PhaseBio Pharmaceuticals, Inc. PHAS
Set alert
0.07 +0.07 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2022
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 1.00
Analyst view
Consensus: hold
Hold
Price target (mean) 1.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35 | -0.39 – -0.30 | -0.66 | +47.0% | 0 | 0.0% | 2 |
| Next quarter | -0.27 | -0.34 – -0.21 | -0.90 | +70.0% | 4.50M | +2748.1% | 2 |
| Current year | -1.19 | -1.30 – -1.08 | -2.98 | +60.1% | 9.32M | -14.0% | 2 |
| Next year | -1.06 | -1.73 – -0.40 | -1.19 | +10.9% | 4.61M | -50.5% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2022 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Sep 27, 2022 | William Blair | Downgrade | Outperform | Market Perform |
| Sep 27, 2022 | Needham | Downgrade | Buy | Hold |
| Aug 14, 2022 | Needham | Maintained | — | Buy |
| Mar 27, 2022 | Needham | Maintained | — | Buy |
| Jun 16, 2021 | Needham | Maintained | — | Buy |
| Mar 15, 2021 | Needham | Maintained | — | Buy |
| Apr 5, 2020 | Citigroup | Maintained | — | Buy |
| Oct 2, 2019 | HC Wainwright & Co. | Initiated | — | Buy |
| Sep 8, 2019 | Stifel | Maintained | — | Buy |